Gene therapy for pancreatitis pain

Area of Science:

• Molecular therapy
• Gene therapy
• Pain management

Background:

• Pancreatitis and pancreatic cancer cause severe, difficult-to-manage pain.
• Alcohol abuse is a primary cause of pancreatitis.
• Novel pain reduction therapies are needed.

Purpose of the Study:

• To review the efficacy of a gene therapy approach for pancreatitis pain.
• To evaluate a herpes simplex virus type 1 (HSV-1) vector encoding the human preproenkephalin gene (HSV-Enk).
• To assess pain alleviation and pancreatic tissue protection in animal models.

Main Methods:

• Utilized a replication-defective HSV-1 viral vector (HSV-Enk) for gene therapy.
• Administered treatment to animal models of alcoholic pancreatitis.
• Evaluated analgesia and pain-related behaviors.
• Assessed pancreatic tissue protection and inflammation.

Main Results:

• HSV-Enk gene therapy provided significant analgesia.
• Pancreatic tissue protection and reduced inflammation were observed.
• Therapeutic effects lasted for the duration of transgene expression (4-6 weeks).

Conclusions:

• HSV-based gene therapy is effective for chronic visceral pain.
• Targeted enkephalin gene therapy offers promise for pain control.
• This approach may benefit patients with pancreatitis and pancreatic cancer pain.